Zabriskie Summer/Leave Research Fellowship
This fellowship, generously endowed by Dr. John L. Zabriskie Jr. '61, is intended to support an intensive Summer or Leave term of research for a student who has begun or is prepared to begin an undergraduate research project with a faculty member. It is generally expected that the Fellow will have completed the Junior year at the time of the award; however, students at other points in their academic career will be considered.
Stipend Information
The student is expected to devote a full-time effort to research during the Summer or Leave research term and will receive a stipend of $6200, paid in monthly increments during the course of the research term.
Applications
The application consists of three parts, submitted to Rebecca J. Talmadge (Rebecca.J.Talmadge@dartmouth.edu)
- A cover page containing the name of the student, the name of the faculty mentor, the title of the research project, and a brief description of the research, including a succinct statement of the overall research goals, the research plan for the research term, and any progress on the project to date;
- A copy of the applicant's transcript; and
- A letter of support from the research mentor.
About John L. Zabriskie Jr. '61 (1939-2014)
This program is supported by a generous endowment from Dr. John L. Zabriskie Jr., a Dartmouth College Chemistry major in the Class of 1961. Dr. Zabriskie conducted undergraduate research at Dartmouth with Professor Thomas Spencer, an experience that led him to continue in Chemistry as his profession.
Dr. Zabriskie received his Ph.D. in Organic Chemistry from the University of Rochester. He was Chairman and CEO of the Upjohn Co. from 1993 to 1995, becoming only the second non-Upjohn family member to lead the pioneering pharmaceutical company during a more than 100-year span, and Chairman and CEO of Pharmacia & Upjohn, Inc. from 1995 to 1997. Pharmacia & Upjohn later became Pharmacia Corp. and was acquired in 2003 by Pfizer, Inc. Dr. Zabriskie served on various Boards of Directors including Array Biopharma, ARCA Biopharma, and the privately held PureTech Ventures. He was a member of the Kellogg Co. Board of Directors from 1995 to 2013.